CN105663032A - 一种维他昔布软膏剂的制备方法 - Google Patents
一种维他昔布软膏剂的制备方法 Download PDFInfo
- Publication number
- CN105663032A CN105663032A CN201610096467.XA CN201610096467A CN105663032A CN 105663032 A CN105663032 A CN 105663032A CN 201610096467 A CN201610096467 A CN 201610096467A CN 105663032 A CN105663032 A CN 105663032A
- Authority
- CN
- China
- Prior art keywords
- ointment
- preparation
- former times
- stirring
- times cloth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002674 ointment Substances 0.000 title claims abstract description 36
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- NSWKPXFHCORWAE-UHFFFAOYSA-N 2-[4-chloro-5-(4-methylphenyl)imidazol-1-yl]-5-methylsulfonylpyridine Chemical compound C1=CC(C)=CC=C1C1=C(Cl)N=CN1C1=CC=C(S(C)(=O)=O)C=N1 NSWKPXFHCORWAE-UHFFFAOYSA-N 0.000 title abstract description 5
- 238000003756 stirring Methods 0.000 claims abstract description 18
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000000203 mixture Substances 0.000 claims abstract description 9
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims abstract description 7
- 229920000053 polysorbate 80 Polymers 0.000 claims abstract description 7
- 229940057995 liquid paraffin Drugs 0.000 claims abstract description 6
- 239000012188 paraffin wax Substances 0.000 claims abstract description 6
- 229940075582 sorbic acid Drugs 0.000 claims abstract description 6
- 235000010199 sorbic acid Nutrition 0.000 claims abstract description 6
- 239000004334 sorbic acid Substances 0.000 claims abstract description 6
- 229940099259 vaseline Drugs 0.000 claims abstract description 6
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims abstract description 4
- 239000004744 fabric Substances 0.000 claims description 28
- 229910002012 Aerosil® Inorganic materials 0.000 claims description 7
- 239000004094 surface-active agent Substances 0.000 claims description 7
- NWGKJDSIEKMTRX-MDZDMXLPSA-N Sorbitan oleate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(O)C1OCC(O)C1O NWGKJDSIEKMTRX-MDZDMXLPSA-N 0.000 claims description 6
- PRXRUNOAOLTIEF-WUOFIQDXSA-N sorbitan trioleate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C\CCCCCCCC)C1OCC(O)C1OC(=O)CCCCCCC\C=C\CCCCCCCC PRXRUNOAOLTIEF-WUOFIQDXSA-N 0.000 claims description 6
- 238000000465 moulding Methods 0.000 claims description 5
- 239000003755 preservative agent Substances 0.000 claims description 4
- 230000002335 preservative effect Effects 0.000 claims description 4
- 239000002562 thickening agent Substances 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- WSWCOQWTEOXDQX-MQQKCMAXSA-N sorbic acid group Chemical group C(\C=C\C=C\C)(=O)O WSWCOQWTEOXDQX-MQQKCMAXSA-N 0.000 claims description 2
- 230000003213 activating effect Effects 0.000 claims 1
- 239000000377 silicon dioxide Substances 0.000 abstract description 2
- 239000007787 solid Substances 0.000 abstract description 2
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 abstract 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 abstract 1
- 238000010438 heat treatment Methods 0.000 abstract 1
- 235000012239 silicon dioxide Nutrition 0.000 abstract 1
- 210000002268 wool Anatomy 0.000 abstract 1
- 241000282472 Canis lupus familiaris Species 0.000 description 7
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 3
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229910021485 fumed silica Inorganic materials 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000012567 medical material Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 239000005416 organic matter Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明涉及一种维他昔布软膏剂的制备方法,该制备方法是分别将凡士林、羊毛脂、固体石蜡、吐温-80、司盘85、司盘80、液体石蜡和山梨酸加入到烧杯中,然后加热至65℃搅拌溶解和均匀,然后加入维他昔布和气相二氧化硅HB-630,搅拌溶解和均匀,室温匀速单一方向搅拌1小时成型,该软膏剂的制备工艺简单,成本低,具有良好的商业化前景。
Description
技术领域
本发明涉及软膏剂的制备方法,具体地说,是一种维他昔布软膏剂的制备方法。
背景技术
维他昔布(Vitacoxib)作为一种新型化合物,为环氧合酶-2(COX-2)抑制剂,具有独特的作用机制即特异性地抑制COX-2,适用于缓解骨关节炎引起的疼痛和炎症,用于骨或软组织手术期治疗管理的药物。
目前维他昔布在宠物护理中的作用越来越明显,调查显示,狗患上关节之类疾病的概率要远远高于人类。人类懂得如何照顾自己,天冷知道添加衣物,而狗狗并不知道。如果没有主人的细心呵护,在寒冷的冬天狗狗也只能休憩冰凉的地面上上。此外,狗又特别喜欢运动奔跑,有时候不小心的跌倒扭伤也会造成对关节、肌肉的伤害。用手术给狗治疗关节炎是比较危险的,目前最好的治疗方案可以口服药物如维他昔布咀嚼片来治疗。另一种治疗方案也可以采用外用软膏剂的方式,由于软膏剂可长时间内紧贴、粘附或铺展在用药部位,起到保护创面、润滑皮肤、局部治疗的作用,软膏剂因其用药方便,效果显著,逐渐深受人们的欢迎。
软膏剂系指原料药、药材、药材的提取物与适宜基质均匀混合制成具有适当稠度的半固体外用制剂,因此软膏剂多用于局部疾病的治疗。
维他昔布不溶于水,在一般的有机溶剂中也不易溶解,本发明根据维他昔布的特点制备了一种完全油相体系下的软膏剂。
为了增加维他昔布在体系中的溶解性,发明中采用了司盘85、司盘80和吐温80三种特点的表面活性剂联合使用作为软膏剂的乳化剂。为了增加软膏剂的稳定性和使用性能,加入了HB-630,HB-630为疏水气相二氧化硅(俗称白炭黑),疏水气相二氧化硅是利用活性有机物与气相二氧化硅表面羟基反应,把有机基团以化学键形式链接到二氧化硅表面,从而使其呈现疏水性质,疏水气相二氧化硅在膏剂中有良好的分散性和界面相容性,并可以提高软膏剂的稠度,从而增加体系的稳定性。
本发明根据维他昔布的结构和性质特点,提供了一种维他昔布软膏剂的制备方法,这种方法的特点是采用了司盘85、司盘80和吐温80三种表面活性剂联合使用作为维他昔布软膏剂的乳化剂,并加入了HB-630这种型号的气相二氧化硅,制备的维他昔布软膏剂性能稳定,流动性和黏附性好,制造成本低,工艺简单,容易进行商业化的生产,制备的维他昔布软膏剂获得了令人振奋和惊奇的结果。
发明内容
本发明的目的是提供一种维他昔布软膏剂的制备方法,该软膏剂的制备工艺简单,成本低,具有良好的商业化前景。
为了达到上述目的,本发明采用以下技术方案:
首先将凡士林、羊毛脂、固体石蜡和液体石蜡加入到烧杯中混合、然后加入表面活性剂和防腐剂,加热至65℃搅拌溶解和均匀,然后加入维他昔布和增稠剂,搅拌溶解和均匀,匀速室温单一方向搅拌1小时成型,按照软膏剂稳定性考察原则进行考察,制备的维他昔布软膏剂符合软膏剂的质量要求。
所述的表面活性剂为吐温-80、司盘85和司盘80三种不同的表面活性剂的混合物。
所述的防腐剂为山梨酸。
所述的增稠剂为气相二氧化硅HB-630。
其特征在于,包含以下步骤:
本发明所述的一种维他昔布软膏剂的制备方法,更具体地,包含以下步骤:首先将凡士林、羊毛脂、固体石蜡和液体石蜡加入到烧杯中混合、然后加入吐温-80、司盘85和司盘80和山梨酸,加热至65℃搅拌溶解和均匀,然后加入维他昔布和气相二氧化硅HB-630,搅拌溶解和均匀,室温匀速单一方向搅拌1小时成型。
具体实施方式
下面是本发明的实施例,所述的实施例只是用来说明本发明,而不应当被视为是对本发明的限制。
实施例
分别将1.0g凡士林、1.0g羊毛脂、0.6g固体石蜡、1.4g吐温-80、1.2g司盘85、2.6g司盘80、11.3g液体石蜡和0.04g山梨酸加入到烧杯中,加热至65℃搅拌溶解和均匀,然后加入0.1g维他昔布和0.8g气相二氧化硅HB-630,搅拌溶解和均匀,室温匀速单一方向搅拌1小时成型。
以上对本发明所提供的一种维他昔布软膏剂的制备方法进行了详细介绍,本文中应用了具体个例对本发明的原理及实施方式进行了阐述,以上实施例的说明只是用于帮助理解本发明的方法及其核心思想;同时,对于本领域的一般技术人员,依据本发明的思想,在具体实施方式及应用范围上均会有改变之处,综上所述,本说明书内容不应理解为对本发明的限制。
Claims (5)
1.一种维他昔布软膏剂的制备方法,其特征在于,包含以下步骤:
首先将凡士林、羊毛脂、固体石蜡和液体石蜡加入到烧杯中混合,然后加入表面活性剂和防腐剂,加热至65℃搅拌溶解和均匀,然后加入维他昔布和增稠剂,搅拌溶解和均匀,室温匀速单一方向搅拌1小时成型,按照软膏剂稳定性考察原则进行考察,制备的维他昔布软膏剂符合软膏剂的质量要求。
2.如权利要求1所述的一种维他昔布软膏剂的制备方法,其特征在于,所述的表面活性剂为吐温-80、司盘85和司盘80三种不同表面活性剂的混合物。
3.如权利要求1所述的一种维他昔布软膏剂的制备方法,其特征在于,所述的防腐剂为山梨酸。
4.如权利要求1所述的一种维他昔布软膏剂的制备方法,其特征在于,所述的增稠剂为气相二氧化硅HB-630。
5.如权利要求1所述的一种维他昔布软膏剂的制备方法,其特征在于,包含以下步骤:
首先将凡士林、羊毛脂、固体石蜡和液体石蜡加入到烧杯中混合、然后加入吐温-80、司盘85、司盘80和山梨酸,加热至65℃搅拌溶解和均匀,然后加入维他昔布和气相二氧化硅HB-630,搅拌溶解和均匀,室温匀速单一方向搅拌1小时成型。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610096467.XA CN105663032A (zh) | 2016-02-23 | 2016-02-23 | 一种维他昔布软膏剂的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610096467.XA CN105663032A (zh) | 2016-02-23 | 2016-02-23 | 一种维他昔布软膏剂的制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105663032A true CN105663032A (zh) | 2016-06-15 |
Family
ID=56305773
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610096467.XA Pending CN105663032A (zh) | 2016-02-23 | 2016-02-23 | 一种维他昔布软膏剂的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105663032A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114734054A (zh) * | 2022-03-30 | 2022-07-12 | 芯体素(杭州)科技发展有限公司 | 一种嵌入式基质及基于该基质的3d打印方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0228568B2 (zh) * | 1981-09-01 | 1990-06-25 | Hisamitsu Pharmaceutical Co | |
CN1469748A (zh) * | 2000-08-29 | 2004-01-21 | ʵ | 用于局部传送环加氧酶-2酶抑制剂的药物组合物 |
CN1547474A (zh) * | 2001-05-31 | 2004-11-17 | 含选择性环加氧酶-2抑制剂及一元醇的可渗透皮肤的组合物 | |
CN1582169A (zh) * | 2001-10-30 | 2005-02-16 | 德古萨股份公司 | 基于热解法生产的二氧化硅的颗粒材料在药物组合物中的用途 |
CN103394091A (zh) * | 2008-06-16 | 2013-11-20 | 帝国制药株式会社 | 消炎镇痛外用剂 |
-
2016
- 2016-02-23 CN CN201610096467.XA patent/CN105663032A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0228568B2 (zh) * | 1981-09-01 | 1990-06-25 | Hisamitsu Pharmaceutical Co | |
CN1469748A (zh) * | 2000-08-29 | 2004-01-21 | ʵ | 用于局部传送环加氧酶-2酶抑制剂的药物组合物 |
CN1547474A (zh) * | 2001-05-31 | 2004-11-17 | 含选择性环加氧酶-2抑制剂及一元醇的可渗透皮肤的组合物 | |
CN1582169A (zh) * | 2001-10-30 | 2005-02-16 | 德古萨股份公司 | 基于热解法生产的二氧化硅的颗粒材料在药物组合物中的用途 |
CN103394091A (zh) * | 2008-06-16 | 2013-11-20 | 帝国制药株式会社 | 消炎镇痛外用剂 |
Non-Patent Citations (3)
Title |
---|
曹艳花,等: "维他昔布的抗炎镇痛作用研究", 《中国药学杂志》 * |
胡英,等: "《药物制剂》", 28 February 2003 * |
莫利特,等: "《乳液、悬浮液、固体配合技术与应用》", 31 October 2003 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114734054A (zh) * | 2022-03-30 | 2022-07-12 | 芯体素(杭州)科技发展有限公司 | 一种嵌入式基质及基于该基质的3d打印方法 |
CN114734054B (zh) * | 2022-03-30 | 2023-09-12 | 芯体素(杭州)科技发展有限公司 | 一种嵌入式基质及基于该基质的3d打印方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102481275B (zh) | 含有布洛芬的表面组合物 | |
JP2005523267A5 (zh) | ||
EP2373346B1 (en) | Ibuprofen for topical administration | |
CN101588789A (zh) | 用于治疗牛和其它动物炎症的药物组合物和方法 | |
CN101631534B (zh) | 用于跨膜给药对乙酰氨基酚的盖仑制剂 | |
CA2340224C (en) | Nimesulide containing topical pharmaceutical compositions | |
CN1850076A (zh) | 一种含苦参碱类生物碱的热敏凝胶剂及其制备方法 | |
JP5217136B2 (ja) | 直腸、尿道および膣適用用半固形状製剤。 | |
CN102440944A (zh) | 一种动物用伊维菌素透皮涂抹剂 | |
CN105663032A (zh) | 一种维他昔布软膏剂的制备方法 | |
CN104161723B (zh) | 一种地克珠利溶液及其制备方法 | |
CN103181894B (zh) | 萘丁美酮喷雾剂及其制备方法 | |
CN107648309A (zh) | 一种消肿止痛的口腔喷雾剂 | |
US20080107735A1 (en) | Macrocyclic formulations for transmembrane drug delivery | |
CN107028977A (zh) | 一种臭氧化油络合物及其制备方法和应用 | |
CN103110573A (zh) | 一种扑尔敏乳膏或凝胶及其制备方法 | |
CN107260670A (zh) | 用于治疗皮肤病症或疾病的新型制剂和方法 | |
CN102670624B (zh) | 一种治疗类风湿性关节炎的贴剂及其制备方法 | |
CN104784115A (zh) | 一种氟比洛芬酯脂微球注射液及其制备方法 | |
CN105055313A (zh) | 一种畜禽使用的复方磺胺类纳米乳制剂及其制备方法 | |
TWI684448B (zh) | 外用醫藥組成物 | |
JPS61200918A (ja) | 外用消炎鎮痛剤 | |
JP7253328B2 (ja) | 外用医薬組成物 | |
CN104523750A (zh) | 用于治疗皮肤病的制剂及其配制方法 | |
Miao et al. | Analysis of dosage form of traditional Chinese medicine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160615 |